Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain uncertain ...
A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West Virginia ...
Introduction and Objectives The Global Initiative for Asthma (GINA) endorse combination inhalers containing an inhaled corticosteroid (ICS) and a fast and long-acting beta-2 agonist (formoterol) as ...
Objectives To integrate evidence from randomised controlled trials (RCTs) and observational studies on the efficacy of inhaled treatments for chronic obstructive pulmonary disease using network ...
Background Achieving disease control (DC) and stability (DS) in COPD could be valuable goals to evaluate treatment effectiveness in real-world settings. Composite endpoints may be useful tools to ...
When patients cannot adhere to inhaler instructions — whether because of cognitive or physical limitations — a nebulized LAMA might offer another method to safely deliver medication. To that end, GOLD ...
Treating Severe Uncontrolled Asthma: Can Single-Inhaler, Fixed Triple-Dose Therapy Improve Outcomes?
Most people with asthma can be effectively managed with an inhaled corticosteroid (ICS), alone or in combination with a long-acting β2-agonist (LABA). However, a significant number of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results